{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/27866"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/27866","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Epitope-Targeted Strategies for Inhibiting Pathogenic Immune Complex Formation in Heparin-Induced Thrombocytopenia","abstract":"Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to the anticoagulant heparin.1,2 HIT is characterized by pathogenic antibodies that form immune complexes with platelet factor 4 (PF4) and heparin, which can cause platelet activation and thrombosis.1,3-6 Prompt diagnosis is crucial because HIT patients experience a 5-10% daily increased risk of thrombotic episodes, which are fatal in up to 30% of patients.2,6-10 The immune response in HIT is polyspecific, resulting in the production of anti-PF4/heparin antibodies that either can (pathogenic) and/or cannot (non-pathogenic) activate platelets.10-12 Differentiating between pathogenic and non-pathogenic antibodies remains a significant diagnostic challenge in HIT, exacerbated by the low specificity and limited availability of current laboratory assays.10,14,15 Previously it was shown that platelet-activating immune complexes form when pathogenic antibodies bind PF4 at a localized region that is distinct from non-pathogenic antibodies.13 In this work, high affinity inhibitors of pathogenic anti-PF4/heparin antibodies were designed using a murine monoclonal antibody (named KKO) that binds to a region on PF4 overlapping with pathogenic antibodies.16 These inhibitors were used to develop a novel diagnostic assay that can detect pathogenic antibodies with improved specificity compared to most standard tests for HIT (specificity ~50-70%).2,15 Enzyme immunoassays (EIAs) are widely used for HIT diagnosis, but have high false-positive rates because they cannot differentiate between pathogenic and non-pathogenic antibodies.10,14,15 This study found that incorporating inhibitors to block clinically significant antibody binding sites on PF4 improved the specificity (90%) of a diagnostic EIA for HIT without sacrificing sensitivity (90-100%). Unlike most high-sensitivity and -specificity diagnostic tests for HIT, such as platelet-activation assays, this EIA can also be performed with technical ease in non-specialized laboratories.","abstract_html":"Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to the anticoagulant heparin.1,2 HIT is characterized by pathogenic antibodies that form immune complexes with platelet factor 4 (PF4) and heparin, which can cause platelet activation and thrombosis.1,3-6 Prompt diagnosis is crucial because HIT patients experience a 5-10% daily increased risk of thrombotic episodes, which are fatal in up to 30% of patients.2,6-10 The immune response in HIT is polyspecific, resulting in the production of anti-PF4/heparin antibodies that either can (pathogenic) and/or cannot (non-pathogenic) activate platelets.10-12 Differentiating between pathogenic and non-pathogenic antibodies remains a significant diagnostic challenge in HIT, exacerbated by the low specificity and limited availability of current laboratory assays.10,14,15 Previously it was shown that platelet-activating immune complexes form when pathogenic antibodies bind PF4 at a localized region that is distinct from non-pathogenic antibodies.13 In this work, high affinity inhibitors of pathogenic anti-PF4/heparin antibodies were designed using a murine monoclonal antibody (named KKO) that binds to a region on PF4 overlapping with pathogenic antibodies.16 These inhibitors were used to develop a novel diagnostic assay that can detect pathogenic antibodies with improved specificity compared to most standard tests for HIT (specificity ~50-70%).2,15 Enzyme immunoassays (EIAs) are widely used for HIT diagnosis, but have high false-positive rates because they cannot differentiate between pathogenic and non-pathogenic antibodies.10,14,15 This study found that incorporating inhibitors to block clinically significant antibody binding sites on PF4 improved the specificity (90%) of a diagnostic EIA for HIT without sacrificing sensitivity (90-100%). Unlike most high-sensitivity and -specificity diagnostic tests for HIT, such as platelet-activation assays, this EIA can also be performed with technical ease in non-specialized laboratories.","abstract_has_math":false,"creators":["Bissola, Anna-Lise"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Biochemistry and Biomedical Sciences","school":null,"contributors":[],"advisors":["Nazy, Ishac"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-11","date_published":"2022-11","updated_at":"2026-11-18T19:37:20Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/18324"],"render_values":[{"text":"https://doi.org/10.71548/18324","href":"https://doi.org/10.71548/18324","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/27866","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/27866","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F27866","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Nazy, Ishac"]},{"key":"dc:contributor.department","label":"Department","values":["Biochemistry and Biomedical Sciences"]},{"key":"dc:creator","label":"Author","values":["Bissola, Anna-Lise"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2022-09-26T18:46:27Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2022-09-26T18:46:27Z"]},{"key":"dc:date.issued","label":"Date","values":["2022-11"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/27866","https://doi.org/10.71548/18324"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to the anticoagulant heparin.1,2 HIT is characterized by pathogenic antibodies that form immune complexes with platelet factor 4 (PF4) and heparin, which can cause platelet activation and thrombosis.1,3-6 Prompt diagnosis is crucial because HIT patients experience a 5-10% daily increased risk of thrombotic episodes, which are fatal in up to 30% of patients.2,6-10 The immune response in HIT is polyspecific, resulting in the production of anti-PF4/heparin antibodies that either can (pathogenic) and/or cannot (non-pathogenic) activate platelets.10-12 Differentiating between pathogenic and non-pathogenic antibodies remains a significant diagnostic challenge in HIT, exacerbated by the low specificity and limited availability of current laboratory assays.10,14,15 Previously it was shown that platelet-activating immune complexes form when pathogenic antibodies bind PF4 at a localized region that is distinct from non-pathogenic antibodies.13 In this work, high affinity inhibitors of pathogenic anti-PF4/heparin antibodies were designed using a murine monoclonal antibody (named KKO) that binds to a region on PF4 overlapping with pathogenic antibodies.16 These inhibitors were used to develop a novel diagnostic assay that can detect pathogenic antibodies with improved specificity compared to most standard tests for HIT (specificity ~50-70%).2,15 Enzyme immunoassays (EIAs) are widely used for HIT diagnosis, but have high false-positive rates because they cannot differentiate between pathogenic and non-pathogenic antibodies.10,14,15 This study found that incorporating inhibitors to block clinically significant antibody binding sites on PF4 improved the specificity (90%) of a diagnostic EIA for HIT without sacrificing sensitivity (90-100%). Unlike most high-sensitivity and -specificity diagnostic tests for HIT, such as platelet-activation assays, this EIA can also be performed with technical ease in non-specialized laboratories."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["Epitope-Targeted Strategies for Inhibiting Pathogenic Immune Complex Formation in Heparin-Induced Thrombocytopenia"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Nazy, Ishac"],"dc:contributor.department":["Biochemistry and Biomedical Sciences"],"dc:creator":["Bissola, Anna-Lise"],"dc:date.accessioned":["2022-09-26T18:46:27Z"],"dc:date.available":["2022-09-26T18:46:27Z"],"dc:date.issued":["2022-11"],"dc:description.abstract":["Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to the anticoagulant heparin.1,2 HIT is characterized by pathogenic antibodies that form immune complexes with platelet factor 4 (PF4) and heparin, which can cause platelet activation and thrombosis.1,3-6 Prompt diagnosis is crucial because HIT patients experience a 5-10% daily increased risk of thrombotic episodes, which are fatal in up to 30% of patients.2,6-10 The immune response in HIT is polyspecific, resulting in the production of anti-PF4/heparin antibodies that either can (pathogenic) and/or cannot (non-pathogenic) activate platelets.10-12 Differentiating between pathogenic and non-pathogenic antibodies remains a significant diagnostic challenge in HIT, exacerbated by the low specificity and limited availability of current laboratory assays.10,14,15 Previously it was shown that platelet-activating immune complexes form when pathogenic antibodies bind PF4 at a localized region that is distinct from non-pathogenic antibodies.13 In this work, high affinity inhibitors of pathogenic anti-PF4/heparin antibodies were designed using a murine monoclonal antibody (named KKO) that binds to a region on PF4 overlapping with pathogenic antibodies.16 These inhibitors were used to develop a novel diagnostic assay that can detect pathogenic antibodies with improved specificity compared to most standard tests for HIT (specificity ~50-70%).2,15 Enzyme immunoassays (EIAs) are widely used for HIT diagnosis, but have high false-positive rates because they cannot differentiate between pathogenic and non-pathogenic antibodies.10,14,15 This study found that incorporating inhibitors to block clinically significant antibody binding sites on PF4 improved the specificity (90%) of a diagnostic EIA for HIT without sacrificing sensitivity (90-100%). Unlike most high-sensitivity and -specificity diagnostic tests for HIT, such as platelet-activation assays, this EIA can also be performed with technical ease in non-specialized laboratories."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/27866","https://doi.org/10.71548/18324"],"dc:language.iso":["en"],"dc:title":["Epitope-Targeted Strategies for Inhibiting Pathogenic Immune Complex Formation in Heparin-Induced Thrombocytopenia"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:37:20Z"}